Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study

Grigoriou, Sotirios LU orcid ; Janz, Carin LU orcid ; Horne, Malcolm ; Bergquist, Filip ; Dizdar, Nil and Odin, Per LU orcid (2025) In Frontiers in Neurology 16.
Abstract
Method: Thirty-two PD patients with sleep disturbances (Clinical Global Impression-Severity (CGI-S) ≥ 3) were included in this observational study. Before start of treatment and during stable dose with rotigotine patients were assessed with Parkinson’s disease sleep scale 2 (PDSS-2), Epworth Sleepiness Scale (ESS), Parkinson’s disease quality of life questionnaire (PDQ-8), European Quality of life five dimensions (EQ-5D-5L) questionnaires and PKG recordings (24 h/day for 6 days). Clinicians evaluated sleep using CGI scales, and PD severity using Clinical Impression of Severity Index for Parkinson’s Disease (CISI-PD).

Results: Rotigotine did not significantly improve total PDSS-2 or PKG nighttime scores in the entire group, but... (More)
Method: Thirty-two PD patients with sleep disturbances (Clinical Global Impression-Severity (CGI-S) ≥ 3) were included in this observational study. Before start of treatment and during stable dose with rotigotine patients were assessed with Parkinson’s disease sleep scale 2 (PDSS-2), Epworth Sleepiness Scale (ESS), Parkinson’s disease quality of life questionnaire (PDQ-8), European Quality of life five dimensions (EQ-5D-5L) questionnaires and PKG recordings (24 h/day for 6 days). Clinicians evaluated sleep using CGI scales, and PD severity using Clinical Impression of Severity Index for Parkinson’s Disease (CISI-PD).

Results: Rotigotine did not significantly improve total PDSS-2 or PKG nighttime scores in the entire group, but PDSS-2 improved among patients with PDSS-2 ≥ 18 at baseline and for DA-naïve patients (p = 0.009 and p = 0.013). Treatment improved percent time tremor (PTT; p < 0.001), percent time immobile during daytime (PTID; p < 0.001), CISI-PD (p < 0.001), PDQ-8 (p = 0.014), and EQ-5D-5L (p = 0.002). No significant correlations were found between PTID and ESS-total (ρ = −0.046, p = 0.718) or between combined sleep score (CSS) and PDSS-2 total (ρ = −0.065, p = 0.612).

Conclusion: Rotigotine improved sleep in patients with a baseline PDSS-2 ≥ 18 and in DA-naïve patients, but not in the whole study group. Additionally, rotigotine seemed to improve motor function and quality of life. PTID improved with treatment. Whether the improved PTID reflects a positive impact on daytime sleepiness or just improved mobility and to what extent PKG nighttime scores accurately represent sleep variables remains to be investigated in further studies. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Parkinson disease, Rotigotine, Sleep disturbance, daytime sleepiness, Dopamine agonist, PKG, Actigraph
in
Frontiers in Neurology
volume
16
publisher
Frontiers Media S. A.
external identifiers
  • pmid:40496128
  • scopus:105007753117
ISSN
1664-2295
DOI
10.3389/fneur.2025.1591537
language
English
LU publication?
yes
id
8c3a92fe-61df-4a47-92d2-45dc1eb969b0
date added to LUP
2025-07-15 22:15:35
date last changed
2025-07-17 15:36:07
@article{8c3a92fe-61df-4a47-92d2-45dc1eb969b0,
  abstract     = {{Method: Thirty-two PD patients with sleep disturbances (Clinical Global Impression-Severity (CGI-S) ≥ 3) were included in this observational study. Before start of treatment and during stable dose with rotigotine patients were assessed with Parkinson’s disease sleep scale 2 (PDSS-2), Epworth Sleepiness Scale (ESS), Parkinson’s disease quality of life questionnaire (PDQ-8), European Quality of life five dimensions (EQ-5D-5L) questionnaires and PKG recordings (24 h/day for 6 days). Clinicians evaluated sleep using CGI scales, and PD severity using Clinical Impression of Severity Index for Parkinson’s Disease (CISI-PD).<br/><br/>Results: Rotigotine did not significantly improve total PDSS-2 or PKG nighttime scores in the entire group, but PDSS-2 improved among patients with PDSS-2 ≥ 18 at baseline and for DA-naïve patients (p = 0.009 and p = 0.013). Treatment improved percent time tremor (PTT; p &lt; 0.001), percent time immobile during daytime (PTID; p &lt; 0.001), CISI-PD (p &lt; 0.001), PDQ-8 (p = 0.014), and EQ-5D-5L (p = 0.002). No significant correlations were found between PTID and ESS-total (ρ = −0.046, p = 0.718) or between combined sleep score (CSS) and PDSS-2 total (ρ = −0.065, p = 0.612).<br/><br/>Conclusion: Rotigotine improved sleep in patients with a baseline PDSS-2 ≥ 18 and in DA-naïve patients, but not in the whole study group. Additionally, rotigotine seemed to improve motor function and quality of life. PTID improved with treatment. Whether the improved PTID reflects a positive impact on daytime sleepiness or just improved mobility and to what extent PKG nighttime scores accurately represent sleep variables remains to be investigated in further studies.}},
  author       = {{Grigoriou, Sotirios and Janz, Carin and Horne, Malcolm and Bergquist, Filip and Dizdar, Nil and Odin, Per}},
  issn         = {{1664-2295}},
  keywords     = {{Parkinson disease; Rotigotine; Sleep disturbance; daytime sleepiness; Dopamine agonist; PKG; Actigraph}},
  language     = {{eng}},
  month        = {{05}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Neurology}},
  title        = {{Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study}},
  url          = {{http://dx.doi.org/10.3389/fneur.2025.1591537}},
  doi          = {{10.3389/fneur.2025.1591537}},
  volume       = {{16}},
  year         = {{2025}},
}